Yorvipath denied for missing prior authorization by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Yorvipath — and How to Navigate It

A prior-authorization-required denial means the claim was processed or the prescription was dispensed before Humana's preapproval was obtained, or that the authorization request was submitted but denied because it did not satisfy Humana's coverage criteria. For Yorvipath (palopegteriparatide), a specialty hormone-replacement therapy for hypoparathyroidism, prior authorization is standard for this drug class and is required because Humana reviews clinical documentation to confirm the diagnosis, prior-treatment history, and medical necessity before approving coverage.

## Why This Is Appealable

If the prior authorization was denied on clinical grounds, that decision is appealable through both the internal and external review process — it is treated identically to any other coverage denial. If the denial occurred because authorization was not obtained in advance, there may be a retroactive authorization process or a coverage-exception pathway. In either case, the same clinical documentation strategy applies: establish the diagnosis, document prior-treatment inadequacy, and satisfy each of Humana's stated authorization criteria with specific chart evidence.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): A prior-authorization denial is subject to the same full-and-fair review rights as any other coverage denial. Submit the appeal — with complete clinical documentation — within the deadline on the denial letter.
• Urgent/concurrent care: If the patient urgently needs the medication and delay is clinically harmful, an expedited review request can compress the timeline to days.
• External review (ACA §2719): If the internal appeal fails, an IRO reviews the clinical record independently. The standard window is up to four months from denial; the IRO's decision binds Humana.
• Retroactive authorization: If the drug was already dispensed, ask Humana's pharmacy or medical management team specifically whether a retroactive authorization request is available and on what timeline.

## Documentation to Gather

1. Diagnosis confirmation — laboratory tests and clinical notes confirming the hypoparathyroidism diagnosis, cause, and duration. 2. Prior-treatment history — a complete, dated list of conventional therapies (calcium and active vitamin D supplementation) used before Yorvipath was requested: agents, duration, clinical response, and documented reason for inadequacy. 3. Clinical severity documentation — chart records showing the burden of disease: symptomatic hypocalcemia episodes, relevant laboratory trends, quality-of-life impact, or end-organ complications. 4. Prescriber medical-necessity letter — addressed specifically to Humana's prior-authorization criteria, answering each criterion with a direct chart reference. 5. Humana's prior-authorization criteria — obtain these from Humana's provider portal or by calling the pharmacy or medical management line. Knowing the exact criteria before writing the appeal is essential.

## Criteria-Mapping Strategy

Humana's prior-authorization criteria for specialty medications typically include: diagnosis confirmation, prior-treatment failure documentation, and clinical severity thresholds. Obtain the exact criteria from Humana's published policy or the authorization denial letter. Then build the appeal as a numbered response to each criterion, citing specific chart records for each. This structure signals to the reviewer that every requirement has been considered and met — the most efficient path to approval.